Dengue vaccine development: II. problems to be solved

Published on May 28, 2015   26 min

You are viewing a talk that is a part of one of our comprehensive courses. Additional learning material: case studies, projects, workshops and recommended reading; multiple choice questions and suggested exam questions with model answers are available on application. Learn more

Other Talks in the Series: Vaccines

So this is the second lecture on current dengue vaccine development, and in the first lecture we described the vaccine under current development, and exactly where they are in the development process. Now we're going to talk about how are we going to implement these vaccines, how we're going to use them, and what problems can we expect, and how can they be solved. So problems to be solved.
And these are the topics that we'll discuss in this lecture. First, when will dengue vaccines come online? Second, what are the global dengue vaccine needs? Third, what are the complexities that we're going to have to confront with, as we've seen, a Sanofi, which is just a partially efficacious vaccine, it's not a 100% against all four viruses. How are we going to immunize the two distinctly different groups who are at risk to dengue disease? And how can we stop or reduce dengue transmission? Fourth, how can dengue vaccines be improved? And here we need to understand the complication of antibody dependent enhancement, abbreviated ADE, and to understand better how protection is induced against dengue infection and disease, both in the natural setting, and also from vaccines. And here we're going to need greater attention to and support from basic research, and finally, the use of a human challenge model in which human beings who have been vaccinated will actually be challenged by a live, somewhat modified dengue virus.

Dengue vaccine development: II. problems to be solved

Embed in course/own notes